Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0175

Congress meeting · Dr. Benedikt Dubois

23 Jan 2026 · In person · Dr. Benedikt Dubois, Memorial Sloan Kettering · MSL Luis Ortega · Lumeva

ReviewedVeeva CRMENG-0175—

Capture insight from this engagement

Location: Memorial Sloan Kettering
Therapeutic area: Neurology
Country: United States
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Real-world persistence

Scientific content used

CGRP class review

Questions raised

What is the persistence rate at 18 months in real-world cohorts?

Notes

Congress meeting with headache specialist at Memorial Sloan Kettering. Discussed real-world persistence.

Insights captured (1)

Capture insight

INS-0054Medium
Real-world persistence
Real-world persistence: request for data reported by headache specialist (US).
Deduplicated

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 5
Depth of exchange: 5
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0175

Audit history (0)

All create, update and approval events for this record

No audit events in sample data